Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

CONMED Corporation CNMD

Healthcare — Medical Devices
Dividend Champion (5y) Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
0.16
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 2 — — — — — — — — — —
Insider Ownership
0.83%

Capital & Financial Ratios

Market Cap
1,380.00
Revenue
1,371.66
Net Income
56.50
Free Cash Flow
134.46
Net Debt
796.92
Current Ratio
1.48
Debt/Equity
0.80
P/E ratio
24.55
P/S ratio
1.00
P/B ratio
1.31
Past 5Y EPS Growth
34.38%
This Y EPS Growth
(1.18%)
Next Y EPS Growth
5.42%
Next 5Y EPS Growth
5.53%
in millions of $

Dividends

Payout Ratio
0.27
Annual Dividend Rate
0.80
Annual Dividend Yield
0.95%
total individual payouts
2027 ‡‡‡‡‡
2026 ‡‡‡‡‡
2025 0.60
—
—
—
2024 0.80
—
—
—
—
2023 0.80
—
—
—
—
2022 0.80
—
—
—
—
2021 0.80
—
—
—
—
2020 0.80
—
—
—
—
2019 0.80
—
—
—
—
2018 0.80
—
—
—
—
2017 0.80
—
—
—
—
2016 0.80
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 24.30 24.46 40.82 37.33
Receivables 242.28 237.73 247.83 239.77
Inventory 318.32 346.72 355.54 360.18
Other — — — —
615.65 640.01 672.86 675.67
2023 2024 2025 Q'26
Payables 88.22 102.25 93.65 101.02
ST’ Debt 0.71 0.72 0.71 177.20
Other 151.73 109.80 138.54 106.77
310.73 278.13 315.04 455.40
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 317.05 343.49 — —
—
’25 321.26 342.35 337.93 373.20
1,374.72
’24 312.27 332.10 316.70 345.94
1,307.02
’23 295.47 317.65 304.58 327.05
1,244.74
’22 242.33 277.19 275.09 250.87
1,045.47
’21 232.68 255.16 248.83 273.97
1,010.64
’20 214.01 157.79 237.84 252.83
862.46
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 13.47 37.10 — —
—
’25 41.53 29.13 53.69 46.34
170.69
’24 29.12 43.31 51.20 43.34
166.97
’23 (3.85) 26.67 46.13 56.40
125.35
’22 0.33 18.74 25.89 (11.60)
33.37
’21 22.34 34.28 21.36 33.79
111.77
’20 3.72 5.54 35.13 20.15
64.53
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 10.58 34.16 — —
—
’25 37.76 23.41 48.50 41.22
150.88
’24 27.09 39.72 47.78 39.30
153.88
’23 (8.10) 22.14 40.73 51.54
106.32
’22 (3.36) 13.03 19.18 (17.27)
11.58
’21 19.24 31.29 15.79 30.60
96.90
’20 0.90 1.79 31.84 17.00
51.52
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.45 0.77 — —
—
’25 0.19 0.69 0.09 0.54
1.51
’24 0.63 0.96 1.57 1.08
4.25
’23 0.06 0.43 0.50 1.05
2.04
’22 0.47 (5.65) 1.48 0.86
(2.68)
’21 0.31 0.41 0.47 0.75
1.94
’20 0.20 (0.96) 0.23 0.81
0.32

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

3.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 71.09 88.01 61.05 38.32 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 155.51 138.47 113.68 74.70 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4,100 4,000 3,900 3,900 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.25 0.31 0.34 0.35 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,045.47 1,244.74 1,307.02 1,374.72 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 54.64% 54.33% 56.08% 54.59% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (70.86) 80.83 163.03 71.12 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.78%) 6.49% 12.47% 5.17% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (80.58) 64.46 132.42 47.06 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 74.43 77.93 77.56 79.93 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 34.80 40.59 42.37 44.29 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ (2.68) 2.10 4.29 1.52 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.11 4.09 5.41 5.50 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.73) (0.62) (0.42) (0.64) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.39 3.47 4.99 4.86 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.82 27.20 31.21 33.29 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30.04 30.67 30.85 31.04 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 52.19 15.95 26.89 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.58 2.71 1.62 0.92 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.62 4.05 2.19 1.22 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.56 3.48 2.29 1.49 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 321.41 40.70 19.45 13.61 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.37 125.35 166.97 170.69 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.78) (19.03) (13.08) (19.81) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.58 106.32 153.88 150.88 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 284.67 304.92 361.88 357.82 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,054.82 973.85 905.78 834.94 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,025.88 949.55 881.32 794.13 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 745.55 834.22 962.68 1,033.10 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.97%) 2.80% 5.75% 2.03% ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 2.47% 4.23% 6.79% 3.51% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (10.53%) 8.16% 14.74% 4.72% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

CONMED Corporation (CNMD) has delivered impressive revenue growth, expanding 71% from $764 million in 2016 to $1.31 billion in 2024 through product innovation and acquisitions like In2Bones, while maintaining strong operational efficiency with revenue per share up 54% and per employee rising 45%. However, the stock has suffered a sharp 70% drawdown from its 2021 peak of $159, reflecting 2022’s goodwill impairment-driven net loss, rising debt, and post-pandemic volatility—leaving it trading at deeply discounted multiples like 1.6x sales and 19x FCF compared to medtech peers.

Balance sheet dynamics show promise amid caution: free cash flow per share surged over 1,200% to $4.99 in 2024, enabling 14% debt reduction to $906 million and ROE recovery to 14.7%, yet insider selling (no buys) and projected 2026 revenue dip (-1%) signal near-term headwinds like reimbursement pressures and rate sensitivity. Analyst targets imply modest 8% mean upside, with valuations suggesting undervaluation but vulnerable to COVID-like stalls.

This quantitative deep dive uncovers mean-reversion potential in CNMD’s fundamentals—blending DCF upside of 15-25% with FCF strength—while flagging downside risks; read the full analysis for detailed projections, correlations, and prudent entry strategies.

Read full commentary →

CONMED Corporation (CNMD) Latest News

News by impact score

Fine-tune

18 Aug

4 , 7:10 AM
Shift in regulatory tailwinds across CONMED's surgical portfolio could alter the bull case for the company. Regulatory shifts in core surgical products may significantly alter CONMED trajectory and investor views.

17 Aug

3 , 3:12 PM
CONMED Corporation's stock (CNMD) rose 16% over the past month, leading investors to assess whether the gains can be sustained. Monthly stock surge of 16% for CNMD signals noticeable shifts in market sentiment that may influence near-term performance without altering core operations.

3 , 3:06 PM
CONMED raises 2026 EPS outlook, potentially bolstering its growth momentum. Raised 2026 EPS guidance points to improved long-term earnings projections.

30 Jul

4 , 6:13 PM
CONMED shares surge after the company reported better-than-expected quarterly results and raised full-year guidance, driving strong investor buying. Beat-and-raise quarter directly lifts revenue and earnings outlook, materially improving near-term stock trajectory.

3 , 12:49 PM
CONMED beat Q2 earnings and revenue estimates with expanded gross margins. Q2 beat and margin growth indicate stronger profitability that can lift near-term stock performance.

29 Jul

4 , 4:27 PM
CONMED Corporation exceeded Q2 CY2026 revenue expectations, triggering a sharp rise in its stock price. Revenue beat directly lifts near-term valuation and investor sentiment for the company.

4 , 4:05 PM
CONMED Corporation reported second quarter 2026 financial results and updated full year 2026 guidance. Quarterly earnings releases with guidance updates typically drive material shifts in stock valuation and investor outlook.

3 transcript www.marketbeat.com, 10:03 PM
CONMED Corporation released Q2 earnings call highlights covering financial results, operational updates and forward guidance. Q2 earnings details and guidance provide moderate insight into near-term financial trajectory and investor sentiment.

3 , 6:30 PM
CONMED Corporation reported Q2 earnings with analysis of key financial metrics. Q2 earnings data can moderately affect investor sentiment and near-term stock performance.

28 Jul

4 , 3:25 AM
CONMED (CNMD) will report Q2 earnings results tomorrow. Q2 earnings release can substantially move CNMD stock and shift investor views.

23 Jul

3 , 12:11 PM
CONMED expands its AirSeal robotic solution to support the da Vinci 5 Hex Cannula. Product expansion strengthens CONMED's robotic surgery offerings and may lift market position.

22 Jul

3 , 7:00 AM
CONMED announces expanded FDA indication for its AirSeal Robotic Solution to enable use with the Intuitive da Vinci 5 Hex Cannula. Expanded indication broadens AirSeal compatibility with da Vinci 5 and supports incremental robotic surgery adoption.

13 Jul

4 stocktwits.com, 12:34 PM
CNMD stock reaches highest level in over four months as JPMorgan highlights the firm's strong appeal to financial acquirers. JPMorgan's view on CONMED's attractiveness to financial buyers points to potential M&A activity that could alter ownership and long-term direction.

4 , 11:25 AM
CONMED shares surge on buyout rumors and approach breakout levels. Buyout rumors signal potential acquisition that can drive major valuation and strategic changes.

10 Jul

4 stocktwits.com, 8:28 PM
CONMED Corporation stock rose as much as 10% after hours on reports of private equity takeover interest. Reports of private equity takeover interest signal a major strategic ownership shift with strong potential to alter company trajectory and investor sentiment.

29 Jun

3 , 11:06 AM
BofA Securities reports CONMED lagging medtech peers as growth slows. Analyst note on slowing growth may pressure near-term stock sentiment and valuation.

1 Jun

3 Simply Wall St., 4:08 PM
CONMED Corporation refreshes its board and enacts governance changes, contributing to ongoing debates over company valuation. Board refresh and governance updates at CONMED influence investor views on strategic oversight and valuation.

4 May

4 Simply Wall St., 8:18 PM
CONMED Corporation (CNMD) shifts focus away from gastroenterology, raising questions on whether this refocus clarifies its long-term surgical growth strategy. Strategic refocus from gastroenterology to surgical growth constitutes a major pivot likely to reshape CONMED's competitive positioning and investor outlook.

2 May

4 StockStory, 12:28 AM
CONMED Corporation exits GI business after Q1 results, refocusing growth efforts on core surgical platforms amid strong performance in orthopedics and general surgery. Exiting non-core GI segment streamlines operations and accelerates growth in high-margin surgical platforms, significantly boosting future trajectory.

30 Apr

4 app.moby.co, 8:30 AM
CONMED Corporation reported Q1 2026 earnings call highlights, detailing financial performance, revenue growth, operational updates, and future outlook. Q1 earnings call summary reveals key financial metrics and guidance shaping CONMED's near-term trajectory and market valuation.

4 Zacks, 8:04 AM
CONMED Corporation's Q1 earnings and revenues beat expectations, leading to an upward revision of the organic sales outlook. Earnings beat and raised organic sales outlook indicate strong financial performance and enhanced growth prospects.

4 GuruFocus.com, 3:16 AM
CONMED Corporation (CNMD) Q1 2026 earnings call highlights focus on navigating operational challenges while capitalizing on growth opportunities. Q1 2026 earnings highlights detail challenges and opportunities shaping CNMD's financial performance, strategy, and investor sentiment.

4 www.marketbeat.com, 12:35 AM
CONMED Corporation reported Q1 earnings call highlights, covering financial results, revenue growth, margin improvements, and updated full-year guidance amid orthopedic and general surgery segment performance. Q1 earnings highlights detail financial metrics, segment growth, and guidance revisions that significantly shape investor expectations and stock trajectory.

29 Apr

4 StockStory, 5:29 PM
CONMED Corporation (NYSE:CNMD) Q1 CY2026 sales exceeded analyst estimates. Q1 CY2026 sales beat signals strong financial performance and lifts investor sentiment significantly.

3 Zacks, 7:30 PM
CONMED Corporation (CNMD) Q1 earnings compared to analyst estimates, with analysis of key metrics. Q1 earnings versus estimates impact financial performance and investor sentiment moderately.

3 Zacks, 6:40 PM
Conmed (CNMD) reported Q1 earnings and revenues that beat analyst estimates. Beating Q1 earnings estimates boosts short-term financial outlook and investor sentiment without fundamentally altering long-term trajectory.

3 Business Wire, 4:05 PM
CONMED Corporation announced first quarter 2026 financial results. Quarterly financial results disclosure impacts key financial metrics and investor sentiment.

28 Apr

3 StockStory, 6:28 AM
CONMED Corporation (CNMD) earnings preview highlights key metrics to watch, including revenue growth, profit margins, guidance outlook, and performance in surgical and orthopedic segments amid market challenges. Earnings previews shape investor expectations around financial results and guidance, moderately influencing short-term market sentiment and stock performance.

9 Apr

3 Zacks, 11:16 AM
CONMED Corporation (CNMD) stock merits retention in portfolios due to robust fundamentals, expanding market share, and promising growth in surgical devices amid positive industry trends. Positive retention advice underscores solid operational strengths and growth potential with moderate effects on investor sentiment and performance.

4 Apr

4 Simply Wall St., 6:09 PM
CONMED beat Q4 earnings expectations and issued a Q1 outlook that could reshape investor perceptions of its margin challenges. Q4 earnings beat and Q1 guidance directly challenge margin concerns, likely boosting investor sentiment and stock trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us